Diazyme Laboratories, Inc.
Explore this company’s associated devices, FDA decisions and regulatory history.

Diazyme Laboratories, Inc.
- Regulatory records
- 2
- Linked recall entries
- 0
- Headquarters
- Not reported
- Brand website
- Not reported
What the linked records show
MedtechLedger currently links 2 FDA records to the applicant name Diazyme Laboratories, Inc.. The collection includes 2 510(k) clearances. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Apr 24, 2026 to Jun 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code DFC appears in 1 of the 2 linked filings. The collection spans 1 FDA product code. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
Applicant mailing address recorded by FDA: 12889 Gregg Ct., Poway, CA, 92130, US. Recorded on K253069, decision dated Jun 16, 2026.
Device categories in this collection
Lipoprotein, Low-Density, Antigen, Antiserum, Control.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Regulatory record history
Lipoprotein (a) Molarity Assay
K253069 · 510(k) clearanceDiazyme Immunoglobulin A Assay; Diazyme Immunoglobulin G Assay; Diazyme Immunoglobulin M Assay
K252336 · 510(k) clearance
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.